A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
← catalyst calendarNCT07213791 · readout ≤ 711 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
241estimated
Sites
30
Countries
China, Germany, Japan +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-22 | actual | When the study began enrolling |
| Primary completion | Jul 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Neoplasms
- Breast Neoplasms
- Pancreatic Intraductal Neoplasms
- Colorectal Neoplasms
- Esophageal Neoplasms
- Stomach Neoplasms
- Cholangiocarcinoma
Intervention
- Drug: LY4337713
Primary outcomes
what the primary-completion date above is the date OFPhase 1a: Percentage of Participants with Dose Limited Toxicity (DLT) Toxicities
measured Cycle 1 (28 days)
Phase 1b: Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)
measured Baseline through imaging follow-up, up to 5 years
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed